CCS
AXDX icon

Crosspoint Capital Strategies’s Accelerate Diagnostics AXDX Stock Holding History

Crosspoint Capital Strategies’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-200
Closed -$52K – 761
2015
Q2 		$52K Buy
+200
New +$47.8K 0.01% 345
2015
Q1 		– Sell
-100
Closed -$19K – 522
2014
Q4 		$19K Buy
+100
New +$21.4K 0.01% 447
2014
Q3 		– Sell
-100
Closed -$20K – 492
2014
Q2 		$20K Buy
+100
New +$21.8K 0.01% 335

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Private Wealth Advisors
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Obermeyer Wealth Partners
Obermeyer Wealth Partners Aspen, Colorado $2.44B AUM 24.34% 1-Year Est. Return

Crosspoint Capital Strategies's AXDX Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Accelerate Diagnostics (AXDX) in Q3 2015, closing a stake of 200 shares — an estimated $52K sold.

Crosspoint Capital Strategies first reported a position in AXDX in Q2 2014 and held it in 3 quarters. The position peaked at $52K in Q2 2015. 88 funds tracked by Wall St. Rank hold AXDX as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining Accelerate Diagnostics position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 200 Accelerate Diagnostics shares in Q3 2015, an estimated $52K.
  • Crosspoint Capital Strategies first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 3 quarters.
  • Crosspoint Capital Strategies's Accelerate Diagnostics position peaked at $52K in Q2 2015.
  • 88 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.